{"editorial":{"content_id":"7b4694e8-2958-4aed-b89f-175e12f1203c","slug":"anvisa-evrysdi-go-20261029-712940","content_type":"news","title":"巴西Anvisa批准Evrysdi Go片剂用于治疗脊髓性肌萎缩症","summary":"巴西国家卫生监督局批准Evrysdi Go（risdiplam）注册，用于治疗2岁以上、体重20公斤起的5q型脊髓性肌萎缩症患者。","body":"巴西国家卫生监督局（Anvisa）于周四（10月29日）批准药物Evrysdi Go（risdiplam）的注册，用于治疗5q型脊髓性肌萎缩症（AME）的成人和2岁以上儿童（体重20公斤起），适用对象为临床诊断为1型、2型或3型、或携带1至4个SMN2基因拷贝的患者。\n\nAME是一种因“运动神经元存活蛋白”（SMN）缺乏导致的遗传病，5q型由运动神经元存活基因位点变异引起。SMN蛋白不足会造成运动神经元丢失，进而导致肌肉无力和肌肉萎缩，影响头部和颈部控制、坐立、爬行、行走等基本活动，呼吸和吞咽相关肌肉也可能受损。\n\nSMN1和SMN2两个基因参与该蛋白的生成。AME患者缺乏SMN1基因，但携带一个或多个SMN2基因拷贝，后者通常产生截短的SMN蛋白，功能低于全长蛋白。Risdiplam是一种小分子药物，可使SMN2基因产生完整蛋白，从而有望提高运动神经元存活率，减轻症状并延缓疾病进展。\n\n该药为包衣片剂，可经少量水送服，或分散于无氯水中以混悬液形式服用。与已获批的risdiplam版本不同，该产品无需医护人员复溶，也无需对照护者进行复杂培训，且储存条件更简单，可在室温下保存而非冷藏。\n\n一项针对41名2至7月龄1型AME（最严重类型）婴儿的研究显示，治疗12个月后，29%（41名中的12名）的婴儿能在无支撑情况下坐立超过5秒。另一项针对180名2型和3型AME患者（年龄至25岁）的研究显示，接受Evrysdi Go治疗的患者运动功能（以MFM32量表评估）略有改善，治疗12个月后与安慰剂相比，在100分制量表上相差1.6分。\n\nAnvisa表示，相关决议4.244/2026已刊登于《联邦官方公报》（DOU）。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["政策","合规","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"source_verified","published_at":"2026-10-29T11:01:20.317Z","display_date":"2026-10-29","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-aprova-medicamento-para-tratamento-da-ame","source_name":"Anvisa","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":[],"opportunity_flags":["market_entry_opportunity"],"trend_signals":[]},"intelligence":{"intel_id":"3aae1701-fc6e-4ea4-a001-2a38160ff126","version":1,"event_type":"监管表态","event_date":"2026-10-29","main_entities":[{"name":"Anvisa","role":"巴西国家卫生监督局，批准Evrysdi Go注册","type":"regulator","country":"巴西","normalized_name":null},{"name":"Evrysdi Go（risdiplam）","role":"获批用于治疗5q型脊髓性肌萎缩症的包衣片剂","type":"product","country":"巴西","normalized_name":null}],"main_action":"Anvisa批准Evrysdi Go片剂注册用于治疗5q型SMA","key_numbers":[{"unit":"岁","label":"适用年龄下限","value":"2"},{"unit":"公斤","label":"适用体重下限","value":"20"},{"unit":"个","label":"SMN2拷贝数范围","value":"1-4"},{"unit":"名","label":"1型AME婴儿研究人数","value":"41"},{"unit":"%","label":"治疗12个月后无支撑坐立超5秒比例","value":"29"},{"unit":"名","label":"2型和3型AME研究患者数","value":"180"},{"unit":"分","label":"MFM32量表差异","value":"1.6"},{"unit":"","label":"Anvisa决议编号","value":"4.244/2026"}],"facts":[{"verified":false,"statement":"Anvisa于周四（10月29日）批准Evrysdi Go（risdiplam）注册，用于治疗5q型脊髓性肌萎缩症的成人和2岁以上儿童（体重20公斤起）。","source_excerpt":null},{"verified":false,"statement":"适用对象为临床诊断为1型、2型或3型，或携带1至4个SMN2基因拷贝的5q型AME患者。","source_excerpt":null},{"verified":false,"statement":"Evrysdi Go为包衣片剂，可经少量水送服，或分散于无氯水中以混悬液形式服用；无需医护人员复溶，也无需对照护者进行复杂培训，可在室温下保存。","source_excerpt":null},{"verified":false,"statement":"针对41名2至7月龄1型AME婴儿的研究显示，治疗12个月后29%的婴儿能在无支撑情况下坐立超过5秒。","source_excerpt":null},{"verified":false,"statement":"针对180名2型和3型AME患者（年龄至25岁）的研究显示，治疗12个月后Evrysdi Go组与安慰剂组在MFM32量表上相差1.6分。","source_excerpt":null},{"verified":false,"statement":"Anvisa表示相关决议4.244/2026已刊登于《联邦官方公报》（DOU）。","source_excerpt":null}],"assessments":[{"statement":"该批准为巴西2岁以上且体重不低于20公斤的5q型SMA患者增加了一种无需复溶、室温储存的口服片剂选择。","confidence":"high","basis_fact_index":null},{"statement":"该剂型可能提升用药便利性和照护可操作性，但实际可及性仍取决于定价、报销覆盖和上市供应。","confidence":"medium","basis_fact_index":null},{"statement":"当前批准范围未覆盖2岁以下或体重低于20公斤的SMA患者。","confidence":"high","basis_fact_index":null}],"actions":[{"target":"both","priority":"high","description":"核验Anvisa决议4.244/2026及DOU原文，确认批准日期、适应症和标签范围。"},{"target":"both","priority":"high","description":"跟踪Evrysdi Go在巴西的上市时间、定价、分销和医保/商业保险覆盖情况。"},{"target":"user","priority":"normal","description":"评估该片剂对巴西SMA治疗产品竞争格局和患者可及性的影响。"}],"affected_audience":["2岁以上且体重不低于20公斤的5q型SMA患者","SMA患者照护者","神经科和儿科医生","药品分销与药房","罕见病支付方"],"risk_flags":[],"opportunity_flags":["market_entry_opportunity"],"trend_signals":[],"follow_up_needed":true,"follow_up_questions":["Evrysdi Go在巴西的定价、报销和上市时间是什么？","该片剂与已获批risdiplam版本在巴西的适应症和供应如何区分？","是否计划扩展至2岁以下或体重低于20公斤患者？","Anvisa决议4.244/2026的具体批准条件是什么？"],"related_topics":["脊髓性肌萎缩症","SMA","Evrysdi Go","risdiplam","Anvisa","药品注册","罕见病","口服片剂"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-10-29T11:01:45.621Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-evrysdi-go-20261029-712940","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-evrysdi-go-20261029-712940","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-evrysdi-go-20261029-712940?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-evrysdi-go-20261029-712940?view=json","last_updated":"2026-10-29T11:01:46.212Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}